Related Experiment Video
Updated: Mar 7, 2026
High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
Published on: March 22, 2011
Seek and destroy: targeted adeno-associated viruses for gene delivery to hepatocellular carcinoma
Bijay Dhungel1,2,3, Aparna Jayachandran1,2, Christopher J Layton2,4
1a Gallipoli Medical Research Institute, Greenslopes Private Hospital , Brisbane , QLD , Australia.
Abstract:
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer with high incidence globally. Increasing mortality and morbidity rates combined with limited treatment options available for advanced HCC press for novel and effective treatment modalities. Gene therapy represents one of the most promising therapeutic options. With the recent approval of herpes simplex virus for advanced melanoma, the field of gene therapy has received a major boost. Adeno-associated virus (AAV) is among the most widely used and effective viral vectors today with safety and efficacy demonstrated in a number of human clinical trials. This review identifies the obstacles for effective AAV based gene delivery to HCC which primarily include host immune responses and off-target effects. These drawbacks could be more pronounced for HCC because of the underlying liver dysfunction in most of the patients. We discuss approaches that could be adopted to tackle these shortcomings and manufacture HCC-targeted vectors. The combination of transductional targeting by modifying the vector capsid and transcriptional targeting using HCC-specific promoters has the potential to produce vectors which can specifically seek HCC and deliver therapeutic gene without significant side effects. Finally, the identification of novel HCC-specific ligands and promoters should facilitate and expedite this process.
Insights
Gene therapy using adeno-associated virus (AAV) vectors shows promise for treating hepatocellular carcinoma (HCC). Overcoming immune responses and off-target effects is key to developing effective HCC-targeted gene delivery systems.
Area of Science:
- Oncology
- Gene Therapy
- Hepatology
Background:
- Hepatocellular carcinoma (HCC) is a prevalent primary liver cancer with high global incidence and increasing mortality.
- Limited treatment options for advanced HCC necessitate the development of novel therapeutic strategies.
- Gene therapy, particularly using viral vectors, is a promising avenue for HCC treatment.
Purpose of the Study:
- To review the obstacles in adeno-associated virus (AAV) based gene delivery for HCC.
- To discuss strategies for manufacturing HCC-targeted AAV vectors.
- To highlight the potential of combining transductional and transcriptional targeting for improved HCC gene therapy.
Main Methods:
- Review of current literature on AAV vectors and HCC gene therapy.
- Identification of challenges including host immune responses and off-target effects.
- Discussion of targeting strategies: modifying vector capsid and using HCC-specific promoters.
Main Results:
- Host immune responses and off-target effects are primary obstacles for AAV gene delivery in HCC.
- Underlying liver dysfunction in HCC patients can exacerbate these drawbacks.
- Combined transductional and transcriptional targeting offers a potential solution for HCC-specific delivery.
Conclusions:
- Developing HCC-targeted AAV vectors requires overcoming immune and off-target challenges.
- Strategies involving capsid modification and HCC-specific promoters are crucial.
- Identification of novel HCC-specific ligands and promoters will accelerate the development of effective gene therapies for liver cancer.
More Related Videos
04:29Efficient Gene Knockdown in the Liver via Intrasplenic Injection of Adeno-Associated Virus Serotype 8 (AAV8)-Delivered Small Hairpin RNA
Published on: November 1, 2024
09:13Study of Viral Vectors in a Three-dimensional Liver Model Repopulated with the Human Hepatocellular Carcinoma Cell Line HepG2
Published on: October 24, 2016